Han B - Search Results

1

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.

Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. Among authors: han b, han h. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Clinical Trial.

2

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.

Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, Bai C, Guo S, Liu W, Zhuang Z, Zhang Y, Zhao Y, Jiang L, Zhou J, Jin X. Han B, et al. J Thorac Oncol. 2011 Jun;6(6):1104-9. doi: 10.1097/JTO.0b013e3182166b6b. J Thorac Oncol. 2011. PMID: 21532504 Free article. Clinical Trial.

3

Pseudomonas aeruginosa preparation plus chemotherapy for advanced non-small-cell lung cancer: a randomized, multicenter, double-blind phase III study.

Chang J, Liu Y, Han B, Zhou C, Bai C, Li J. Chang J, et al. Among authors: han b. Med Oncol. 2015 May;32(5):139. doi: 10.1007/s12032-015-0583-1. Epub 2015 Mar 24. Med Oncol. 2015. PMID: 25801231 Clinical Trial.

4

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study.

Reck M, Hagiwara K, Han B, Tjulandin S, Grohé C, Yokoi T, Morabito A, Novello S, Arriola E, Molinier O, McCormack R, Ratcliffe M, Normanno N. Reck M, et al. Among authors: han b. J Thorac Oncol. 2016 Oct;11(10):1682-9. doi: 10.1016/j.jtho.2016.05.036. Epub 2016 Jul 25. J Thorac Oncol. 2016. PMID: 27468938 Free article.

5

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Mok TS, et al. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6. N Engl J Med. 2017. PMID: 27959700 Free PMC article. Clinical Trial.

6

A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Yang JC, Mok T, Han B, Orlando M, Puri T, Park K. Yang JC, et al. Among authors: han b. Clin Lung Cancer. 2018 Jan;19(1):27-34. doi: 10.1016/j.cllc.2017.06.013. Epub 2017 Jul 6. Clin Lung Cancer. 2018. PMID: 28743421 Free article. Review.

7

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.

8

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC.

Chen Y, Yang Z, Wang Y, Hu M, Zhang B, Zhang Y, Qian F, Zhang W, Han B. Chen Y, et al. Among authors: han b. Front Oncol. 2021 Apr 16;11:671228. doi: 10.3389/fonc.2021.671228. eCollection 2021. Front Oncol. 2021. PMID: 33937084 Free PMC article.

9

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study.

Chen Y, Wang Y, Yang Z, Hu M, Zhang Y, Qian F, Zhang W, Zhang B, Han B. Chen Y, et al. Among authors: han b. Front Oncol. 2021 Jun 28;11:691519. doi: 10.3389/fonc.2021.691519. eCollection 2021. Front Oncol. 2021. PMID: 34262873 Free PMC article.

10

Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer.

Yang Z, Chen Y, Wang Y, Hu M, Qian F, Zhang Y, Zhang B, Zhang W, Han B. Yang Z, et al. Among authors: han b. Front Immunol. 2022 Feb 14;13:807575. doi: 10.3389/fimmu.2022.807575. eCollection 2022. Front Immunol. 2022. PMID: 35237263 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9,310 results

Search Page